• breast cancer - HR positive
• es-BC - HR positive - (neo)adjuvant (NA) 2
• es-BC - HR-positive - 1st line (L1) 1
• la/mBC - HR positive 2
• la/mBC - HR positive - (neo)adjuvant (NA) 3
• la/mBC - HR positive - NA - PIK3CA mutant
• la/mBC - HR-positive - 1st line (L1) 13
• la/mBC - HR positive - L1 - PIK3CA mutant 1
• la/mBC - HR-positive - 2nd line (L2) 20
• la/mBC - HR positive - L2 - all population 1
• la/mBC - HR positive - L2 - PIK3CA mutant 1

 

• AKT inhibitor
• capivasertib based treatment
• capivasertib plus paclitaxel
• ipatasertib based treatment
• ipatasertib plus paclitaxel
• cyclin inhibitor
• abemaciclib based treatment
• abemaciclib plus aromatase inhibitor
• abemaciclib plus endocrine therapy
• palbociclib based treatment
• palbociclib plus endocrine therapy
• palbociclib plus letrozole
• ribociclib based treatment
• ribociclib plus letrozole
• HER inhibitor
• HER2 inhibitor
• trastuzumab based treatment
• trastuzumab plus endocrine therapy
• TKI anti HER1/EGFR and HER2/neu
• lapatinib based treatment
• lapatinib plus fulvestrant
• lapatinib plus letrozole
• IGF-1R inhibitors
• dalotuzumab plus ridaforolimus plus exemestane
• VEGF(R) inhibitor
• cediranib plus fulvestrant

• versus all
• vs chemotherapy
• vs non platinum-based chemotherapy
• vs taxanes
• vs paclitaxel
• vs endocrine therapy
• vs aromatase inhibitor
• vs exemestane
• vs exemestane plus ridaforolimus
• vs fulvestrant
• vs letrozole
• vs HER inhibitor
• vs HER2 inhibitor
• vs trastuzumab based treatment
• vs trastuzumab plus chemotherapy

• study list
• mapping
• overview
• meta-analysis
• forest plot
• NMA
• excluded

Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS)

Comparator:  vs aromatase inhibitor;   vs endocrine therapy;   vs letrozole; 
Risk of bias:  low;   some concerns;   high;  NA;